Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma - PubMed (original) (raw)
doi: 10.1038/ng.2493. Epub 2012 Dec 2.
Rebecca J Leary, Siân Jones, Jian Wu, C Patrick Reynolds, Xueyuan Liu, Amanda Blackford, Giovanni Parmigiani, Luis A Diaz Jr, Nickolas Papadopoulos, Bert Vogelstein, Kenneth W Kinzler, Victor E Velculescu, Michael D Hogarty
Affiliations
- PMID: 23202128
- PMCID: PMC3557959
- DOI: 10.1038/ng.2493
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
Mark Sausen et al. Nat Genet. 2013 Jan.
Abstract
Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children. To determine the genetic basis for neuroblastoma, we performed whole-genome sequencing (6 cases), exome sequencing (16 cases), genome-wide rearrangement analyses (32 cases) and targeted analyses of specific genomic loci (40 cases) using massively parallel sequencing. On average, each tumor had 19 somatic alterations in coding genes (range of 3-70). Among genes not previously known to be involved in neuroblastoma, chromosomal deletions and sequence alterations of the chromatin-remodeling genes ARID1A and ARID1B were identified in 8 of 71 tumors (11%) and were associated with early treatment failure and decreased survival. Using tumor-specific structural alterations, we developed an approach to identify rearranged DNA fragments in sera, providing personalized biomarkers for minimal residual disease detection and monitoring. These results highlight the dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of patients with neuroblastoma.
Conflict of interest statement
COMPETING FINANCIAL INTERESTS
L.A.D., N.P., B.V., K.W.K., and V.E.V are founders of Inostics and Personal Genome Diagnostics and are members of their Scientific Advisory Boards. L.A.D., N.P., B.V., K.W.K., and V.E.V. own Inostics and Personal Genome Diagnostics stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict-of-interest policies.
Figures
Figure 1. Number and type of somatic alterations detected in each neuroblastoma case
The vertical axis includes non-synonymous single base substitutions, insertions, deletions, and splice site changes (NS Mutations), homozygous deletions and amplifications affecting protein encoding genes, and rearrangements with at least one breakpoint within the coding region of a gene. The inset shows the mutation spectra of somatic non-silent single nucleotide mutations in 16 cases of neuroblastoma. Data on rearrangements and copy number changes were not available for starred samples.
Figure 2. Genomic alterations in ARID1A and ARID1B
The schematic represents the ARID1B and ARID1A proteins with the predicted effects of observed intragenic deletions and point mutations.
Figure 3. Overall survival according to ARID1 status
The hazard ratio for death among patients with wildtype ARID1B/A (n=48), as compared to those with mutant ARID1B/A (n = 7) was 4.49 (95% confidence interval, CI 1.24–16.33; _P_=0.0226, log-rank test). The median survival was 1689 days for patients with wildtype ARID1B/A compared to 386 days for patients with mutated ARID1B/A. An analysis that also included hemizygous deletions of the entire coding region of ARIDB further increased the significance of the survival difference between patients with mutant and wildtype ARID1B/A (hazard ratio, HR 6.41; 95% confidence interval, CI 1.93–21.25; P=0.0024, log-rank test).
Similar articles
- ARID1B alterations identify aggressive tumors in neuroblastoma.
Lee SH, Kim JS, Zheng S, Huse JT, Bae JS, Lee JW, Yoo KH, Koo HH, Kyung S, Park WY, Sung KW. Lee SH, et al. Oncotarget. 2017 Jul 11;8(28):45943-45950. doi: 10.18632/oncotarget.17500. Oncotarget. 2017. PMID: 28521285 Free PMC article. - Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.
Bellini A, Bessoltane-Bentahar N, Bhalshankar J, Clement N, Raynal V, Baulande S, Bernard V, Danzon A, Chicard M, Colmet-Daage L, Pierron G, Le Roux L, Planchon JM, Combaret V, Lapouble E, Corradini N, Thebaud E, Gambart M, Valteau-Couanet D, Michon J, Louis-Brennetot C, Janoueix-Lerosey I, Defachelles AS, Bourdeaut F, Delattre O, Schleiermacher G. Bellini A, et al. Int J Cancer. 2019 Nov 15;145(10):2781-2791. doi: 10.1002/ijc.32361. Epub 2019 May 31. Int J Cancer. 2019. PMID: 31018240 Free PMC article. - Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.
Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, Angiuoli SV, Sausen M, Kann L, Shukla M, Makar R, Wood LD, Diaz LA Jr, Lengauer C, Velculescu VE. Jones S, et al. Nat Commun. 2014 Sep 19;5:5006. doi: 10.1038/ncomms6006. Nat Commun. 2014. PMID: 25233892 Free PMC article. - An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa.
Yamamoto H, Watanabe Y, Maehata T, Morita R, Yoshida Y, Oikawa R, Ishigooka S, Ozawa S, Matsuo Y, Hosoya K, Yamashita M, Taniguchi H, Nosho K, Suzuki H, Yasuda H, Shinomura Y, Itoh F. Yamamoto H, et al. World J Gastroenterol. 2014 Apr 14;20(14):3927-37. doi: 10.3748/wjg.v20.i14.3927. World J Gastroenterol. 2014. PMID: 24744582 Free PMC article. Review. - Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.
Deyell RJ, Attiyeh EF. Deyell RJ, et al. Cancer Genet. 2011 Mar;204(3):113-21. doi: 10.1016/j.cancergen.2011.03.001. Cancer Genet. 2011. PMID: 21504710 Review.
Cited by
- Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity.
Xu M, Hong JJ, Zhang X, Sun M, Liu X, Kang J, Stack H, Fang W, Lei H, Lacoste X, Okada R, Jung R, Nguyen R, Shern JF, Thiele CJ, Liu Z. Xu M, et al. EMBO J. 2024 Aug 22. doi: 10.1038/s44318-024-00206-1. Online ahead of print. EMBO J. 2024. PMID: 39174852 - A comprehensive overview of liquid biopsy applications in pediatric solid tumors.
Janssen FW, Lak NSM, Janda CY, Kester LA, Meister MT, Merks JHM, van den Heuvel-Eibrink MM, van Noesel MM, Zsiros J, Tytgat GAM, Looijenga LHJ. Janssen FW, et al. NPJ Precis Oncol. 2024 Aug 3;8(1):172. doi: 10.1038/s41698-024-00657-z. NPJ Precis Oncol. 2024. PMID: 39097671 Free PMC article. Review. - Deciphering the Epigenetic Symphony of Cancer: Insights and Epigenetic Therapies Implications.
Akram F, Tanveer R, Andleeb S, Shah FI, Ahmad T, Shehzadi S, Akhtar AM, Syed G. Akram F, et al. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241250317. doi: 10.1177/15330338241250317. Technol Cancer Res Treat. 2024. PMID: 38780251 Free PMC article. Review. - Developmental origins shape the paediatric cancer genome.
Chen X, Yang W, Roberts CWM, Zhang J. Chen X, et al. Nat Rev Cancer. 2024 Jun;24(6):382-398. doi: 10.1038/s41568-024-00684-9. Epub 2024 May 2. Nat Rev Cancer. 2024. PMID: 38698126 Review. - Phenotypic Heterogeneity, Bidirectionality, Universal Cues, Plasticity, Mechanics, and the Tumor Microenvironment Drive Cancer Metastasis.
Mierke CT. Mierke CT. Biomolecules. 2024 Feb 3;14(2):184. doi: 10.3390/biom14020184. Biomolecules. 2024. PMID: 38397421 Free PMC article. Review.
References
- Ries LAG, SM, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR. NIH Publication. 99-4649. National Cancer Institute, SEER Program; Bethesda, MD: 1999. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995.
- Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. - PubMed
- Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65–84. - PubMed
- Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep. 2009;11:431–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials